Subcorneal Pustular Dermatosis Successfully Treated with Acitretin in a Patient with Glucose-6-Phosphatase Deficiency Dehydrogenase Deficiency

Hosseinpour, Mojgan DO,1 Baigrie, Dana DO,2 Crane, Jonathan DO2

1Department of Dermatology at St. Barnabas Hospital, Bronx, NY
2Department of Dermatology at Campbell University School of Osteopathic Medicine Sampson Regional Medical Center, Clinton, NC

ABSTRACT

Subcorneal pustular dermatosis (SPD) is a rare neutrophilic dermatosis. SPD most commonly presents as a serpiginous pattern of pustules on the trunk or intertriginous areas of middle-aged females. It tends to have a chronic disease course and patients may experience relapses. Dapsone currently remains the treatment of choice for SPD. However, in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency, alternative therapies are required. We report a case of subcorneal pustular dermatosis in a G6PD deficient patient successfully treated with acitretin.

CASE REPORT

A 71-year-old African American woman presented for evaluation of a painful and pruritic rash of the right lower extremity that had developed one year prior. She was referred by her primary care physician after treatment with trimethoprim-sulfamethoxazole and clotrimazole for suspected bacterial and dermatophyte infection without resolution. At the dermatology office, she was initially evaluated by a physician assistant and found to have excoriated plaques on the right proximal pretibial region and right distal calf. A shave biopsy was performed revealing an impetiginized nummular dermatitis. Triamcinolone acetonide 0.1% ointment was prescribed for twice daily use with modest improvement in her skin lesions. She was eventually diagnosed with pustular psoriasis based on clinical findings and started on topical treatment with calcipotriene 0.005% topical ointment to use twice daily. Upon follow-up evaluation four months later, the rash continued to spread and the patient reported draining lesions and worsening pruritus despite compliance with topical therapy. At this visit, she was evaluated by the dermatologist.

On examination, the patient was found to have crops of erythematous scaly papules and plaques studded with pustules distributed on the trunk, upper and lower extremities (Figure 1-4). Two punch biopsies were performed and direct immunofluorescence (DIF) was requested. The patient was instructed to discontinue calcipotriene and begin prednisone 20 mg daily for one week. On follow-up evaluation one week later, annular and serpiginous erythematous patches and peripheral
pustules were noted on physical examination. The pathology results revealed subcorneal collections of neutrophils with negative DIF study (Figure 5). Based on clinical and histopathological examination, findings were most consistent with subcorneal pustular dermatosis. The patient was counseled on the risks, benefits and alternatives to starting dapsone therapy. A glucose-6-phosphate dehydrogenase (G6PD) level and baseline labs were ordered prior to initiating treatment with dapsone. She was found to be G6PD deficient on repeated laboratory analysis. Therefore, she was started on acitretin 25mg once daily in addition to a one-week course of oral corticosteroids. The patient was also evaluated by her primary care physician in search of a gammopathy or associated comorbidity, which was unremarkable. The patient has shown immense clinical improvement on acitretin with minimal to no adverse effects. After approximately eight months of therapy with acitretin, the lesions cleared with some residual post-inflammatory hyperpigmentation. The patient experienced a relapse of her skin disease and was restarted on acitretin 25mg once daily and subsequently increased to 25mg twice daily. Once she maintained clearance, she was titrated down to acitretin 25mg once daily and remained well-controlled on a scheduled dose of 25mg every other day.

**PRACTICE POINTS**

- Subcorneal pustular dermatosis is a rare, chronic, pustular eruption typically presenting in middle-aged women on the trunk, in intertriginous areas and on the limbs.
- Although the mainstay of therapy is dapsone, oral retinoids may produce rapid and complete resolution of symptoms for patients in which dapsone is contraindicated.
Subcorneal pustular dermatosis, also referred to as Sneddon-Wilkinson disease, is a rare, pruritic, pustular eruption that is distributed typically on the trunk, intertriginous areas and limbs. It commonly presents in middle-aged women and may be associated with lymphoproliferative disorders such as IgA or IgG gammopathies or myelomas. The condition may also be associated with cancer, infection, medications or systemic or autoimmune diseases. The primary cutaneous lesion is a superficial, flaccid pustule arising on a somewhat erythematous base that subsequently ruptures and develops crusting or scale. The lesions may coalesce to form an annular or serpiginous pattern and tend to be symmetrically distributed.

The etiology of subcorneal pustular dermatosis is unknown. The condition tends to have a chronic course with relapses and remissions over many years. The pathophysiology of subcorneal pustular dermatosis...
Subcorneal pustular dermatosis is a rare neutrophillic skin disorder that can significantly impact a patient’s quality of life. It typically presents in middle-aged women as polycyclic or serpiginous pustules that which can be diagnostically challenging. The treatment of choice is dapsone at a dose of 50-200mg daily, which typically produces complete remission within 4 weeks. However, our patient had G6PD deficiency, an inherited X-linked metabolic disorder that affects red blood cell function. Unlike most cells in the body, red blood cells only have one enzyme to catalyze dehydrogenase reactions necessary for metabolism. Metabolism of dapsone produces toxic metabolites with directly-acting hemolytic properties. In patients with decreased activity of the G6PD enzyme, red blood cells become more vulnerable to oxidative stress resulting in acute hemolytic anemia. Retinoids such as acitretin have comparable efficacy to dapsone. They act more rapidly and are better tolerated. Previous literature report eruptions healing within 2 weeks of therapy and complete clearance within 8 months. Acitretin is believed to exert its therapeutic effects by inhibiting neutrophil migration and function. Most patients tend to have dramatic improvement of symptoms within 1 week of starting low-dose retinoids. Dapsone has risk for serious toxicities such as hemolytic anemia and methemoglobinemia. Treatment can be refractory in many cases requiring maintenance therapy to prevent relapses. With low-dose acitretin, 0.5mg/kg/day, the most frequently report adverse effect was cheilitis. Alternative treatments including corticosteroid therapy and phototherapy are less effective.

Subcorneal pustular dermatosis is a rare neutrophillic skin disorder that can significantly impact a patient’s quality of life. It typically presents in middle-aged women as polycyclic or serpiginous pustules that
rupture and form superficially crusted plaques. Though lesions may resolve relatively rapidly (within approximately four weeks) when treated with dapsone, certain situations such as failed response or contraindications to therapy may necessitate alternative treatments considerations. Our patient was G6PD deficient, therefore dapsone was dismissed as a treatment option and the patient was started on acitretin, an oral retinoid. She remains clear and off of the medication eight months after treatment initiation.

Conflict of Interest Disclosures: None

Funding: None

Corresponding Author:
Dana Baigrie DO
Department of Dermatology
Sampson Regional Medical Center
1099 Medical Center Drive #201
Wilmington NC 28412
Phone: 850-241-6862
Fax: 910-343-6006
e-mail: dbaigrie@vcom.edu

References:
1. Cohen PR. Sweet’s syndrome - a comprehensive review of an acute febrile neutrophilic dermatosis. Orphanet J Rare Dis. 2007;2:34.
2. Canpolat F, Akpinar H, Cemil BC, Eskioglu F, Ozturk E. A case of subcorneal pustular dermatosis in association with monoclonal IgA gammopathy successfully treated with acitretin. J Dermatol Treat 2010; 21: 114-6.
3. Marlière V, Beylot-Barry M, Beylot C, Dourte M. Successful treatment of subcorneal pustular dermatosis (Sneddon–Wilkinson disease) by acitretin: Report of a case. Dermatology. 1999;199:153–155.
4. Teixeira M, Alves R, Selores M. Subcorneal pustular dermatosis in association with a monoclonal igA gammopathy: Successful treatment with acitretin. Eur J Dermatol. 2006;16:588–590.
5. James, W. D., Elston, D. M., Berger, T. G., & Andrews, G. C. Seborrheic Dermatitis, Psoriasis, Recalcitrant Palmoplantar Eruptions, Pustular Dermatitis, and Erythroderma in Andrews' Diseases of the skin: Clinical dermatology. 2011;10(3)185-198.
6. Sanchez, NP, HO Perry, SA Muller, R K Winkelmann. Subcorneal Pustular Dermatosis and Pustular PsoriasisA Clinicopathologic Correlation. Arch Dermatol. 1983;119(9):715-721.
7. Khosravi-Hafshejani T, Dutz JP. Chronic annular pustular psoriasis resembling subcorneal pustular dermatosis: A case report. SAGE Open Med Case Rep. 2019;7:2050313X19857392.
8. Luzzatto L., Nannelli C. & Notaro R. Glucose-6-Phosphate Dehydrogenase Deficiency. Hematol Oncol Clin N. 2016;30:373–93.